According to a recent statistic, there will be an upwards of 16,688,780 of estimated cancer detection cases, in 2017, not to mention the worrying number of deaths. Sensitization is where we should start if we want to mitigate these cases. Talking about awareness and trying to find out new ways to curb the epidemic, no known review journal has done better regarding demystification than Oncotarget.
This is a worldwide peer review journal that focuses on the pathological basis of all cancers. Oncotarget was started in 2010, published by Impact Journal and is a member and conforms to the set Principles of the Committee on Publication Ethics, COPE. COPE is a body made up of top editors and publishers and is charged with ensuring that all publications in the peer review journals adhere to all publication ethics. On the other hand, COPE advises editors on how to handle cases of research and publication flaws and misconducts. Read more about Oncotarget at Google Scholar.
In the recent past, this journal has gotten famous, due to its punctual, insightful, and constructive reviews that help its researchers to deepen their research on this deadly disease. It helps to make known potential targets, treatment procedures, and protocols and also helps cancer patients to manage their condition. Readers learn about the newest therapies available today, evidence to show and support the fact that these treatments work, and also helps them better accept their condition, thus living a quality life.
Other than Oncology, this journal also welcomes papers on various topics such as Neuroscience, Cell Biology, Endocrinology, Cardiology, Metabolism, and Pharmacology amongst many other disciplines.
This journal has a popular editorial bar consisting of the former editor in chief of Cancer Research, Board Carlo M. Croce, and Andrew Schally, who is also a Nobel Prize winner. Schally has had his ten papers published on Oncortaget. This journal boasts of having, since its inception, 4 of its members, Bert Vogelstein, Michael N. Hall, Alexander Varshavsky, and Stephen J. Elledge winning the Breakthrough Prize. This prize is considered the highest price ever. Learn more about Oncotarget at Research Gate.